Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 33Thoracic 4Sarcoma 3Head & Neck 3Gynecologic 3Breast 3Tumor-Agnostic 2Other neoplasm 1Endocrine 1CNS 1

Conditions

Ovarian Neoplasms 2Gestational Trophoblastic Disease 1

Interventions

Paclitaxel 140pembrolizumab 119Carboplatin 104Bevacizumab 90Cisplatin 67Specimen Handling 62Magnetic Resonance Spectroscopy 51olaparib 50Gemcitabine 39Nivolumab 36Biopsy 36liposomal doxorubicin 32Taxes 31Cyclophosphamide 31Blood Specimen Collection 29niraparib 27lenvatinib 26Letrozole 26Doxorubicin 26Topotecan 25Drug Therapy 25Immunoglobulin G 22fludarabine 21atezolizumab 21Radiotherapy 21Brachytherapy 21Disulfides 20durvalumab 19Surveys and Questionnaires 19dostarlimab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
apatinib × Gynecologic × 1 year × Clear all
NCT02867956 2026-03-10

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

Sun Yat-sen University

Phase 2 Completed
35 enrolled
Gynecologic

Ovarian Neoplasms

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Recruiting
48 enrolled
Gynecologic

Ovarian Neoplasms

NCT05139095 2026-02-05

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Peking Union Medical College Hospital

Phase 2 Recruiting
70 enrolled
Gynecologic

Gestational Trophoblastic Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡